- Home
- MNKD
MNKD
MannKind Corporation
as 12-18-2024 10:40am EST
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
| Founded: | 1991 | Country: | United States |
| Employees: | N/A | City: | DANBURY |
| Market Cap: | 1.8B | IPO Year: | 2004 |
| Target Price: | $8.40 | AVG Volume (30 days): | 2.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.17 - $7.63 | Next Earning Date: | 11-07-2024 |
| Revenue: | $267,200,000 | Revenue Growth: | 51.35% |
| Revenue Growth (this year): | 45.36% | Revenue Growth (next year): | 16.99% |
Stock Insider Trading Activity of MannKind Corporation (MNKD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Binder Steven B. | MNKD | Director | Nov 22 '24 | Sell | $6.89 | 67,536 | $465,323.04 | 1,075,026 | |
| Tross Stuart A | MNKD | Chief People & Workpl Officer | Nov 6 '24 | Sell | $7.34 | 55,000 | $403,700.00 | 967,191 |
Latest MannKind Corporation News
MNKD Breaking Stock News: Dive into MNKD Ticker-Specific Updates for Smart Investing
MT Newswires
3 hours ago
MannKind Launches Exchange of Convertible Notes With Cash, Common Stock
GlobeNewswire
4 hours ago
MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash
MT Newswires
2 days ago
MannKind Says 6-Month Results of Phase 3 Study for Inhaled Insulin Afrezza Meet Primary Endpoint
GlobeNewswire
2 days ago
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)
MT Newswires
7 days ago
MannKind, Cipla Say Afrezza Inhalation Powder Approved for Diabetes in India
GlobeNewswire
7 days ago
CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India
Simply Wall St.
a month ago
MannKind Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Thomson Reuters StreetEvents
a month ago
Q3 2024 MannKind Corp Earnings Call
Compare MNKD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MNKD MannKind Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.